Shares of Resverlogix Corp. (TSE:RVX – Get Free Report) dropped 11.1% on Friday . The stock traded as low as C$0.08 and last traded at C$0.08. Approximately 164,578 shares traded hands during trading, an increase of 61% from the average daily volume of 102,461 shares. The stock had previously closed at C$0.09.
Resverlogix Price Performance
The firm has a 50-day moving average of C$0.10 and a two-hundred day moving average of C$0.13. The company has a market capitalization of C$24.10 million, a PE ratio of -2.25 and a beta of 0.53.
About Resverlogix
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases.
Featured Articles
- Five stocks we like better than Resverlogix
- 3 Tickers Leading a Meme Stock Revival
- 2 Stocks to Get You Ready for the Holiday Season
- Upcoming IPO Stock Lockup Period, Explained
- Profit Potential: 5 Undervalued Stocks With High Dividend Yields
- Technology Stocks Explained: Here’s What to Know About Tech
- MarketBeat Week in Review – 8/21 – 8/25
Receive News & Ratings for Resverlogix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Resverlogix and related companies with MarketBeat.com's FREE daily email newsletter.
